Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children. - sprookjes - yvandenbroek - TriplyDB

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

http://www.wikidata.org/entity/Q35122827

about

Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge.Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study).A Novel Squirrel Respirovirus with Putative Zoonotic Potential Isolation and characterization of novel bat paramyxovirus B16-40 potentially belonging to the proposed genus Shaanvirus

P2860

Q37118707-C4E5EB71-B6B1-4A62-A37F-79B16A6944FD Q37578465-C3AD68DB-1151-4E81-9EAA-AC63F6160D8E Q40163240-0094664F-A0CF-45C0-B2F6-FCFF89E50C1E Q47555408-87BDA6CD-D24C-428A-BF18-68214AE44135 Q55366271-FB2E0A30-8B4D-43A3-B8BD-AD5C6DE9FEDF Q56561972-D7638D71-161A-4D72-BB4C-2740F5E671B1 Q56891587-D5FB687E-C41C-47E5-816C-9002B778D1AC

P2860

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

http://www.wikidata.org/entity/Q35122827

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Safety and immunogenicity of a ...... in 3- to 6-year-old children.

@ast

Safety and immunogenicity of a ...... in 3- to 6-year-old children.

@en

type

label

Safety and immunogenicity of a ...... in 3- to 6-year-old children.

@ast

Safety and immunogenicity of a ...... in 3- to 6-year-old children.

@en

prefLabel

Safety and immunogenicity of a ...... in 3- to 6-year-old children.

@ast

Safety and immunogenicity of a ...... in 3- to 6-year-old children.

@en

P1433

Q35122827-6EE918AA-8550-4A63-A419-8F8EB522846B

P1476

Q35122827-3DACDFF9-2D34-4C8B-9247-56D45E8503B4

P2093

Q35122827-1408C029-64AB-4D86-B547-1474675AA6E5

Q35122827-1FEC259C-1597-4A42-BA36-0A5CBF7A6780

Q35122827-2C2F3D43-7D54-4F5D-A4B9-AFC41B9757DC

Q35122827-5D657C82-87B2-4780-B4F6-6F3FFC8B24CE

Q35122827-5FE0CD94-39F3-4976-8146-38F92723F906

Q35122827-75A326DE-D32C-4500-9CE9-30B821FE73AD

Q35122827-84940FC1-61C9-40F1-BF66-F42989EE337E

Q35122827-8BB80F6A-ED62-4F59-9ECA-9473FF134E35

Q35122827-9079F6B9-7D2B-408F-98B3-DDB40BD39DDC

Q35122827-9770EFEB-1F5C-40CD-883E-EBCF32E2F76B

P2860

Q35122827-02432A08-9CB3-4B07-8DD8-205E89E4C191

Q35122827-0FAF1FED-51C0-4636-9D84-0C4541DD98E2

Q35122827-1ED49F88-6390-4188-96F2-5093741A2720

Q35122827-2CCC41F0-71FB-4105-8B65-68D6F57BE8D6

Q35122827-2D66FC3B-AED3-41CE-81A4-AB7CD0095D02

Q35122827-34F70E5F-0FC7-40C5-9403-1C1071FA5E16

Q35122827-35ECD754-0EB1-40D0-BED7-72433470FB09

Q35122827-47274E92-FE15-4B1B-AC22-8E362957B140

Q35122827-48CF6064-F00F-4246-B185-5EB3EFF9F20B

Q35122827-6153BBB3-3F3D-4B01-8864-B04B690BDE0B

P304

Q35122827-4F0DF048-0EDD-4977-909E-95BD231407BE

P31

Q35122827-F37AAA29-2F03-4759-A07F-89B3FBFB3C4C

P356

Q35122827-A598BECD-C413-4272-9D7D-C18B68D513C9

P433

Q35122827-2472AEA4-0166-493A-9317-BBA06879E8FC

P478

Q35122827-9CD99FE5-2537-49FC-9008-D8629407968C

P577

Q35122827-E1190E3C-E42E-4D34-B806-615FBC4AC6C0

P698

Q35122827-C9E49DFF-F184-450E-94BB-7FED4BE27C07

P921

Q35122827-C5E451BD-F663-4717-90F8-406A3906A66E

P932

Q35122827-9C8F3521-F8A0-4FB7-BBAB-264503DCAA8D

P356

P1433

Clinical and Vaccine Immunology

P1476

Safety and immunogenicity of a ...... in 3- to 6-year-old children.

@en

P2093

Aditya H Gaur

http://www.w3.org/2001/XMLSchema#string

Allen Portner

http://www.w3.org/2001/XMLSchema#string

Bart G Jones

http://www.w3.org/2001/XMLSchema#string

Charles J Russell

http://www.w3.org/2001/XMLSchema#string

Elisabeth Adderson

http://www.w3.org/2001/XMLSchema#string

James Knight

http://www.w3.org/2001/XMLSchema#string

Jill Utech

http://www.w3.org/2001/XMLSchema#string

Jim Allay

http://www.w3.org/2001/XMLSchema#string

Julia L Hurwitz

http://www.w3.org/2001/XMLSchema#string

Karen S Slobod

http://www.w3.org/2001/XMLSchema#string

P2860

The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity.

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus.

Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut

Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment.

P304

298-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.00618-14

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25552633

http://www.w3.org/2001/XMLSchema#string

P921

P932

4340902

http://www.w3.org/2001/XMLSchema#string